Robust U.S. IPO activity through September 2026, with 247 listings year-to-date and over $137 billion raised in the first half alone, reflects strong equity market receptivity fueled by AI-driven demand and improved aftermarket performance. Mega-deals such as SpaceX have anchored the surge, while recent and imminent offerings—including ADARx Pharmaceuticals on September 25 and Oura on September 30—signal sustained window openness amid constructive book-building and pricing within or above ranges. Key swing factors for late-2026 debuts include post-election timing, valuation discipline for high-profile names like Anthropic (targeting a possible November launch) versus 2027 signals from OpenAI and Databricks, plus broader influences from Treasury yields, risk appetite, and regulatory filings. Market-implied odds aggregate trader consensus on these near-term catalysts through year-end.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedPerplexity remains private with no confirmed IPO before the deadline
Available reporting continues to describe Perplexity as private and its CEO’s stated target as 2028. No official IPO completion or filing by the market deadline was found in the supplied material, supporting the low endpoint price.

































Beware of external links.
Beware of external links.
Frequently Asked Questions